LSIA
GTBP icon

LaSalle St. Investment Advisors’s GT Biopharma GTBP Stock Holding History

LaSalle St. Investment Advisors’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.49K Buy
+11,000
New +$6K ﹤0.01% 411

Other funds holding GTBP

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
I
INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return

LaSalle St. Investment Advisors's GTBP Position: Q1 2026 in Review

LaSalle St. Investment Advisors opened a new position in GT Biopharma (GTBP) in Q1 2026: 11,000 shares worth $4.49K. The stake represents ﹤0.01% of the portfolio and ranks #411 among its holdings.

42 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

  • LaSalle St. Investment Advisors held 11,000 shares of GT Biopharma worth $4.49K as of Q1 2026.
  • GT Biopharma was a new LaSalle St. Investment Advisors position in Q1 2026.
  • GT Biopharma made up ﹤0.01% of LaSalle St. Investment Advisors's portfolio in Q1 2026, its #411 holding.
  • 42 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on LaSalle St. Investment Advisors's 13F filing for Q1 2026, filed 8 May 2026.